Ignite Creation Date:
2025-12-24 @ 4:38 PM
Ignite Modification Date:
2026-01-28 @ 4:01 AM
Study NCT ID:
NCT04622566
Status:
UNKNOWN
Last Update Posted:
2020-11-13
First Post:
2020-10-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma
Sponsor:
Peking University Cancer Hospital & Institute
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
MK59132
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None